Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.
As outlined in ACI’s report “Health Guidance Levels for THC in CBD products,” the industry group recommend that the UK Home Office enacts a cap of 0.021 mg/kg of THC (and other cannabinol derivatives) per day. This limit would be equivalent to permitting 0.03 percent THC per the recommended 70 mg daily intake of CBD.
ACI member Treehouse Biotech has submitted a Novel Foods application to UK authorities for its Cannabidiol (CBD)-based ingredients in a move that signals the US firm’s intent to capture a slice of the UK’s burgeoning CBD market.
Pharmacy Business Magazine reports that the FSA updated the criteria for CBD products which can remain on sale from 1 April 2021. Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.
Last February, the Food Standards Agency (FSA) announced that all CBD businesses operating in England and Wales must have a novel foods application “validated” by March 31, 2021, or risk having their CBD oils, drinks, and treats “taken off the shelves.” Now, with just over two weeks left until the deadline, the FSA has clarified that all applications just have to be “submitted” by March 31, 2021.
Coverage from the US publication Hemp Grower on the requirement for novel foods applications to sell CBD products in the UK.
[Cannavist] The Food Standards Agency (FSA) has updated its criteria for CBD products to remain on sale after April 1
Previously, only products that were on sale on February 13, 2020 and linked to an application that had been validated by the March 31, 2021 deadline could continue to be sold.
The criteria for CBD products which can remain on sale from 1 April 2021 has been updated by the Food Standards Agency (FSA).